The mucopolysaccharidoses are lysosomal disorders that progressively affect most organ systems in the body usually beginning in childhood. Recent treatment advances have produced some amelioration, but notably brain and bone have been difficult to treat. The long-term objectives of this research are to identify abnormalities of central nervous system (CNS) structure and function over time using quantitative neuropsychological, behavioral, and MRI techniques;to identify, those measures that are most sensitive to change;and to identify the impact of biological, environmental, and disease factors on outcomes. Findings in the current research have suggested 1) white matter is abnormal in both structure and function;2) significant psychosocial problems as MPS children age;and 3) need for better measurements.
Our specific aims are 1) to study corpus callosum and white matter volumes, diffusion tensor imaging (DTI) and a new MRI technique, resting state fMRI, by disease subtype over time compared to normal controls and in relationship to neuropsychological functions such as attention. 2) We will examine the impact of biological, environmental, and disease related factors on emotional and social function. 3) We will develop more precise outcome measures. In particular, we will develop an MPS-specific and sensitive quality-of-life measure that will measure both physical and psychosocial difficulties. Measurement of gait, physical symptom severity, pain, and disability will also be considered in relationship to emotional/social function and quality-of-life. Methods: We will accomplish this with 120+ patients, recruited in the past 4 years from 6 centers (70 MPS I, 30 MPS II, and 20 MPS VI). Each patient will be seen for a total of 3 or 4 follow-up visits with quantitative neuroimaging (volumetrics/DTI for all;fMRI for older patients) and neuropsychological tests (IQ, attention, memory, visual spatial) as well as adaptive behavior, quality-of-life and emotion including behavior, temperament, and self-esteem. Data will be analyzed for 1) age changes in white matter and psychological adjustment, 2) the sensitivity of measures to disease progression, and 3) variables that contribute to outcomes. These results will enable prevention and interventions to enhance long-term functional outcomes.

Public Health Relevance

Neurobehavioral function and quality-of-life are compromised in many patients with MPS disorders. This research can 1) more accurately inform patients/parents regarding potential neurobehavioral outcomes, 2) develop sensitive measures of disease progression and CNS treatment outcome, and 3) help clinical researchers develop direct treatments to specific brain structures/functions.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Program Officer
Morris, Jill A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Mauer, Michael; Glynn, Emily; Svarstad, Einar et al. (2014) Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLoS One 9:e112188
Rumsey, Robin K; Rudser, Kyle; Delaney, Kathleen et al. (2014) Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA. J Pediatr 164:1147-1151.e1
Schiffmann, Raphael; Forni, Sabrina; Swift, Caren et al. (2014) Risk of death in heart disease is associated with elevated urinary globotriaosylceramide. J Am Heart Assoc 3:e000394
Polgreen, Lynda E; Thomas, William; Fung, Ellen et al. (2014) Low bone mineral content and challenges in interpretation of dual-energy X-ray absorptiometry in children with mucopolysaccharidosis types I, II, and VI. J Clin Densitom 17:200-6
Polgreen, Lynda E; Thomas, William; Orchard, Paul J et al. (2014) Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab 111:101-6
Stevenson, David A; Rudser, Kyle; Kunin-Batson, Alicia et al. (2014) Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI. J Pediatr Rehabil Med 7:159-65
Prater, Sean N; Banugaria, Suhrad G; Morgan, Claire et al. (2014) Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis 37:141-3
Schiffmann, Raphael; Mayfield, Joan; Swift, Caren et al. (2014) Quantitative neuroimaging in mucolipidosis type IV. Mol Genet Metab 111:147-51
Wang, Raymond Y; Braunlin, Elizabeth A; Rudser, Kyle D et al. (2014) Carotid intima-media thickness is increased in patients with treated mucopolysaccharidosis types I and II, and correlates with arterial stiffness. Mol Genet Metab 111:128-32
Ahmed, Alia; Whitley, Chester B; Cooksley, Renee et al. (2014) Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the *-L-iduronidase gene in Hurler-Scheie syndrome. Mol Genet Metab 111:123-7

Showing the most recent 10 out of 34 publications